Large gap with delayed quotes
|
Last quote
04/22/2025 -
13:40:37
|
Bid
04/22/2025 -
13:40:37
|
Bid Volume |
Ask
04/22/2025 -
13:40:37
|
Ask Volume |
|---|---|---|---|---|
|
26.55
0.00
(
0.00% )
|
26.55
|
2,700 |
26.70
|
2,346 |
Analysis date: 18.04.2025
Global Evaluation
Positive
Positive
The stock is classified in the positive zone since 18.04.2025.
Interest
Very strong
Very strong
Four stars since 18.04.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 01.10.2024 at a price of 36.10.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 25.02.2025.
4wk Rel Perf
-15.72%
-15.72%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 15.72% behind the STOXX600.
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 25.03.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by 0.06%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.34%.
Mkt Cap in $bn
1.78
1.78
With a market capitalization <$2bn, BB BIOTECH AG is considered a small-cap stock.
G/PE Ratio
45.30
45.30
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
3.85
3.85
The estimated PE is for the year 2025.
LT Growth
164.24%
164.24%
The annualized growth estimate is for the current year to 2025.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
10.21%
10.21%
The twelve month estimated dividend yield represents 39.32% of earnings forecasts.
Beta
87
87
For 1% of index variation, the stock varies on average by 0.87%.
Correlation
0.46
0.46
46.48% of stock movements are explained by index variations.
Value at Risk
1.60
1.60
The value at risk is estimated at CHF 1.60. The risk is therefore 6.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.07.2014
22.07.2014